Carlos Peniche

Carlos Peniche requested an update on the TissueCypher sales reps, including their current number, expansion plans for the year, and their contribution to the test's growth. Carlos Peniche also inquired about the opportunity to penetrate private equity roll-ups for TissueCypher, whether it's driving growth, and if it remains a future growth driver or if efforts have shifted.

Answer

Derek Maetzold, Founder, President, and CEO of Castle Biosciences, stated that the company continues to add to the TissueCypher sales team throughout the year. He indicated that both dermatology and GI specialties are expected to require fewer than 100 sales reps, and the company is methodically working towards that number. Derek Maetzold clarified that 2025 TissueCypher growth was largely organic, driven by individual clinicians. He confirmed that targeting large group models, including private equity groups, to promote uniform Barrett's Esophagus treatment for quality standards and patient care, is an important and developing strategy for the gastroenterology sales force and strategic accounts team, with expected fruition in 2026.

Carlos Peniche requested an update on the TissueCypher sales reps, including their current number, expansion plans for the year, and their contribution to the test's growth. Carlos Peniche also inquired about the opportunity to penetrate private equity roll-ups for TissueCypher, whether it's driving growth, and if it remains a future growth driver or if efforts have shifted.

Answer

Derek Maetzold, Founder, President, and CEO of Castle Biosciences, stated that the company continues to add to the TissueCypher sales team throughout the year. He indicated that both dermatology and GI specialties are expected to require fewer than 100 sales reps, and the company is methodically working towards that number. Derek Maetzold clarified that 2025 TissueCypher growth was largely organic, driven by individual clinicians. He confirmed that targeting large group models, including private equity groups, to promote uniform Barrett's Esophagus treatment for quality standards and patient care, is an important and developing strategy for the gastroenterology sales force and strategic accounts team, with expected fruition in 2026.